Pfizer begins early-stage study of oral Covid-19 drug

Pfizer begins early-stage study of oral Covid-19 drug
Pfizer begins early-stage study of oral Covid-19 drug

Hello and welcome to the details of Pfizer begins early-stage study of oral Covid-19 drug and now with the details

Nevin Al Sukari - Sana'a - The drugmaker, which developed the first authorised Covid-19 vaccine in the US with Germany’s BioNTech SA, said the antiviral candidate showed potent activity against SARS-CoV-2. — Reuters pic

Subscribe to our Telegram channel for the latest updates on news you need to know.


WASHINGTON, March 23 — Pfizer Inc has started an early-stage US trial of an oral Covid-19 antiviral therapy that could be prescribed to patients at the first sign of infection, the company said today.

The drugmaker, which developed the first authorised Covid-19 vaccine in the US with Germany’s BioNTech SA, said the antiviral candidate showed potent activity against SARS-CoV-2, the virus that causes Covid-19, in lab studies.

Pfizer’s candidate, named PF-07321332, is a protease inhibitor that prevents the virus from replicating in cells.

Protease inhibitors have been effective at treating other viral pathogens such as HIV and hepatitis C virus, both on their own and in combination with other antivirals, the company said.

Pfizer believes this class of molecules may provide well-tolerated treatments against Covid-19, as currently marketed therapeutics that work on the same lines have not reported safety concerns.

The company is also studying an intravenously administered antiviral candidate in an early-stage trial in hospitalised Covid-19 patients.

“Together, the two (oral and intravenous candidates) have the potential to create an end-to-end treatment paradigm that complements vaccination in cases where disease still occurs,” Pfizer’s Chief Medical Officer Mikael Dolsten said in a statement.

Pfizer’s candidate is behind two other oral antiviral therapies, which are in mid-stage trials – the first being developed by rival Merck & Co with Ridgeback Bio, and a second from Roche Holding and Atea Pharmaceuticals.

Gilead Sciences’ remdesivir is currently the only US Food and Drug Administration-approved drug for the treatment of Covid-19.

The FDA has granted an emergency authorization to intravenous therapies from Eli Lilly - bamlanivimab alone and in combination with etesevimab, and a combination therapy from Regeneron. — Reuters

These were the details of the news Pfizer begins early-stage study of oral Covid-19 drug for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at Malay Mail and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

PREV Biden sees pushback on China but ready to see Xi, says aide
NEXT Alpha, Beta, Gamma, Delta — WHO uses Greek alphabet to name COVID-19 variants